How many drugs treat Diabetes mellitus type 2?

Drug Landscape tracks 10 marketed treatments for Diabetes mellitus type 2 (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Diabetes mellitus type 2?

Most recent: Invokana — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/diabetes-mellitus-type-2.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Diabetes mellitus type 2 — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Diabetes mellitus type 2 (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Diabetes mellitus type 2, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Brenzavvy	BEXAGLIFLOZIN	Theracosbio	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2023-01-01
Mounjaro	TIRZEPATIDE	Eli Lilly	Dual GIP/GLP-1 receptor agonist	GIP receptor and GLP-1 receptor	2022-01-01
Ozempic	semaglutide	Novo Nordisk	GLP-1 Receptor Agonist [EPC]	GLP-1 receptor	2017-01-01
Steglatro	ERTUGLIFLOZIN	Merck & Co.		Low affinity sodium-glucose cotransporter	2017-01-01
Adlyxin	LIXISENATIDE	Sanofi-Aventis Us Llc	Insulin Analog [EPC]	Glucagon-like peptide 1 receptor	2016-01-01
Suganon	EVOGLIPTIN	Dong-A ST		Dipeptidyl peptidase 4	2015-01-01
Farxiga	DAPAGLIFLOZIN	AstraZeneca	Sodium-Glucose Cotransporter 2 Inhibitor	Sodium/glucose cotransporter 2	2014-01-01
Albugon	ALBIGLUTIDE	GSK	GLP-1 Receptor Agonist	Glucagon-like peptide 1 receptor	2014-01-01
Jardiance	empagliflozin	Boehringer Ingelheim	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	SGLT2	2014-01-01
Trulicity	DULAGLUTIDE	Eli Lilly	GLP-1 Receptor Agonist [EPC]	GLP-1 receptor	2014-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-04-20 — Invokana · FDA · approved · US
2026-04-14 — Invokana · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-04-06 — Farxiga · FDA · approved · US
2026-03-30 — Saxenda · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 13 drugs in Diabetes mellitus type 2
Pfizer · 5 drugs in Diabetes mellitus type 2
Eli Lilly · 5 drugs in Diabetes mellitus type 2
Sanofi · 3 drugs in Diabetes mellitus type 2
Boehringer Ingelheim · 3 drugs in Diabetes mellitus type 2
AstraZeneca · 2 drugs in Diabetes mellitus type 2
Takeda · 2 drugs in Diabetes mellitus type 2
Novo Nordisk · 2 drugs in Diabetes mellitus type 2
GSK · 1 drug in Diabetes mellitus type 2
Chong Kun Dang · 1 drug in Diabetes mellitus type 2
EMS · 1 drug in Diabetes mellitus type 2
Bayer · 1 drug in Diabetes mellitus type 2

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Diabetes mellitus type 2:

Cite this brief

Drug Landscape (2026). Diabetes mellitus type 2 — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diabetes-mellitus-type-2. Accessed 2026-06-10.

Diabetes mellitus type 2 full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing